Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 7,628 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 43
States / cities: Beverly Hills, California • Encino, California • National City, California + 37 more

Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel; Drug · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1286
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 815 more

Conditions: Ischemic Stroke
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Breast Neoplasms
Interventions: THERATOPE® vaccine; Drug
Lead sponsor: Oncothyreon Canada Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 17
States / cities: Berkeley, California • San Francisco, California • Santa Monica, California + 14 more

Conditions: Barrett Syndrome, Barrett's Syndrome, Barrett's Esophagus, Barrett Esophagus, Adenocarcinoma
Interventions: Standard endoscopic evaluation, pCLE guided evaluation; Device
Lead sponsor: Mauna Kea Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Jacksonville, Florida • Chicago, Illinois • Kansas City, Missouri + 1 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions: FlorenceM (US) and FlorenceX (UK), Insulin pump therapy; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years to 18 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone; Drug
Lead sponsor: UNICANCER; Other
Eligibility: 18 Years and older · Female only
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 17
States / cities: Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more

Conditions: Crohn's Disease
Interventions: Placebo, ABT-874; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 36
States / cities: Orange, California • San Diego, California • Hamden, Connecticut + 30 more

Conditions: Clostridium Difficile
Interventions: SER-109, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Oceanside, California • Sacramento, California • Ventura, California + 26 more

Conditions: Sickle Cell Disease
Interventions: Voxelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months to 11 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 33
States / cities: Phoenix, Arizona • San Diego, California • Wilmington, Delaware + 20 more

Conditions: Degenerative Disc Disease
Interventions: HEALOS and Leopard Cage, Leopard Cage and Autograft; Device
Lead sponsor: Advanced Technologies and Regenerative Medicine, LLC (ATRM); Other
Eligibility: 18 Years to 70 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 17
States / cities: Little Rock, Arkansas • Beverly Hills, California • Brandon, Florida + 14 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Discussion, Medical Chart Review, Questionnaire Administration; Behavioral · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 15 Years to 39 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 480
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 302 more

Conditions: Crohn's Disease
Interventions: Trichuris suis ova (TSO), Placebo; Biological
Lead sponsor: Coronado Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 64 more

Conditions: Multiple Myeloma
Interventions: Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 197
States / cities: Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more

Conditions: Post-endoscopic Mucosal Resection of Colon Polyps
Interventions: Olympus CF190 Colonoscope High definition white light, Olympus CF190 Colonoscope White light with near focus, Olympus CF190 Colonoscope Narrow band imaging, Olympus CF190 Colonoscope Narrow band imaging with near focus, Biopsy; Device · Procedure
Lead sponsor: Michael Wallace; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 112
States / cities: Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more

Conditions: Advanced Cancers Associated With Mesothelin Expression
Interventions: HPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target, 2 Prime Step IV 900-14000 ng/kg Target; Biological
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Metastatic Uveal Melanoma
Interventions: RP2, Ipilimumab, Nivolumab; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: Not listed
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 29
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 90 Years
Enrollment: 1,141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 42 more

Conditions: Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions: Ethosuximide, Lamotrigine, Valproic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 30 Months to 13 Years
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more

Conditions: Post Operative Bowel Dysfunction
Interventions: Methylnaltrexone (MOA-728); Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 59
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Chula Vista, California + 51 more

Search by objective public record fields.

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Day and Night Closed-loop in Young People With Type 1 Diabetes

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease

Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Assessing a Endoscopic Mucosal Resection Site Using Different Endoscopic Imaging Methods

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Alzheimer's Disease Neuroimaging Initiative 3

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus